(PODD) Insulet - Overview
Stock: Insulin Pump, Automated Delivery, Wireless Pods, Drug Device
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.1% |
| Relative Tail Risk | -9.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -28.54 |
| Character TTM | |
|---|---|
| Beta | 0.816 |
| Beta Downside | 1.143 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.31% |
| CAGR/Max DD | -0.10 |
Description: PODD Insulet December 19, 2025
Insulet Corporation (NASDAQ:PODD) designs, manufactures, and markets tubeless insulin-delivery systems for people with insulin-dependent diabetes, primarily through its Omnipod platform. The Omnipod 5 combines a proprietary automated insulin-delivery (AID) algorithm with Bluetooth-linked continuous glucose monitoring, while the Omnipod DASH uses a smartphone-style personal diabetes manager to control a Bluetooth-enabled pod. Insulet also supplies pods to Amgen for the Neulasta Onpro chemotherapy kit and distributes its products via pharmacies and independent distributors.
Key recent metrics: FY 2023 revenue reached roughly $2.5 billion, up about 16 % YoY, driven by a ~30 % market-share position in the U.S. tubeless pump segment and expanding adoption of automated insulin delivery. Gross margins have remained high at ~70 %, reflecting the premium nature of the hardware and software bundle, while R&D spending stays near 10 % of revenue to sustain algorithm improvements. A macro driver is the continued rise in diabetes prevalence-over 10 % of U.S. adults-supporting long-term demand for advanced insulin-delivery solutions.
For a deeper quantitative assessment, you may find ValueRay’s platform useful for drilling into Insulet’s valuation metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 246.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.74 > 1.0 |
| NWC/Revenue: 48.05% < 20% (prev 67.31%; Δ -19.26% < -1%) |
| CFO/TA 0.18 > 3% & CFO 533.7m > Net Income 246.2m |
| Net Debt (273.9m) to EBITDA (451.2m): 0.61 < 3 |
| Current Ratio: 2.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.7m) vs 12m ago -4.45% < -2% |
| Gross Margin: 71.46% > 18% (prev 0.69%; Δ 7077 % > 0.5%) |
| Asset Turnover: 83.30% > 50% (prev 65.57%; Δ 17.73% > 0%) |
| Interest Coverage Ratio: 6.85 > 6 (EBITDA TTM 451.2m / Interest Expense TTM 53.1m) |
Altman Z'' 3.76
| A: 0.40 (Total Current Assets 1.86b - Total Current Liabilities 647.7m) / Total Assets 3.03b |
| B: 0.06 (Retained Earnings 185.8m / Total Assets 3.03b) |
| C: 0.12 (EBIT TTM 363.7m / Avg Total Assets 3.03b) |
| D: 0.12 (Book Value of Equity 199.0m / Total Liabilities 1.65b) |
| Altman-Z'' Score: 3.76 = AA |
Beneish M -3.03
| DSRI: 0.97 (Receivables 462.2m/375.6m, Revenue 2.52b/1.98b) |
| GMI: 0.97 (GM 71.46% / 69.36%) |
| AQI: 0.93 (AQ_t 0.15 / AQ_t-1 0.16) |
| SGI: 1.27 (Revenue 2.52b / 1.98b) |
| TATA: -0.09 (NI 246.2m - CFO 533.7m) / TA 3.03b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of PODD shares?
Over the past week, the price has changed by -5.43%, over one month by -17.81%, over three months by -25.19% and over the past year by -15.90%.
Is PODD a buy, sell or hold?
- StrongBuy: 14
- Buy: 6
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PODD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 370.4 | 53.1% |
| Analysts Target Price | 370.4 | 53.1% |
| ValueRay Target Price | 238.7 | -1.3% |
PODD Fundamental Data Overview February 03, 2026
P/E Forward = 41.841
P/S = 7.1406
P/B = 12.9636
P/EG = 1.9377
Revenue TTM = 2.52b USD
EBIT TTM = 363.7m USD
EBITDA TTM = 451.2m USD
Long Term Debt = 934.9m USD (from longTermDebt, last quarter)
Short Term Debt = 96.4m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 273.9m USD (from netDebt column, last quarter)
Enterprise Value = 18.28b USD (18.01b + Debt 1.03b - CCE 757.4m)
Interest Coverage Ratio = 6.85 (Ebit TTM 363.7m / Interest Expense TTM 53.1m)
EV/FCF = 43.40x (Enterprise Value 18.28b / FCF TTM 421.2m)
FCF Yield = 2.30% (FCF TTM 421.2m / Enterprise Value 18.28b)
FCF Margin = 16.70% (FCF TTM 421.2m / Revenue TTM 2.52b)
Net Margin = 9.76% (Net Income TTM 246.2m / Revenue TTM 2.52b)
Gross Margin = 71.46% ((Revenue TTM 2.52b - Cost of Revenue TTM 719.7m) / Revenue TTM)
Gross Margin QoQ = 72.22% (prev 69.67%)
Tobins Q-Ratio = 6.03 (Enterprise Value 18.28b / Total Assets 3.03b)
Interest Expense / Debt = 1.51% (Interest Expense 15.6m / Debt 1.03b)
Taxrate = 28.66% (35.2m / 122.8m)
NOPAT = 259.4m (EBIT 363.7m * (1 - 28.66%))
Current Ratio = 2.87 (Total Current Assets 1.86b / Total Current Liabilities 647.7m)
Debt / Equity = 0.75 (Debt 1.03b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 0.61 (Net Debt 273.9m / EBITDA 451.2m)
Debt / FCF = 0.65 (Net Debt 273.9m / FCF TTM 421.2m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 246.2m / Total Assets 3.03b)
RoE = 18.27% (Net Income TTM 246.2m / Total Stockholder Equity 1.35b)
RoCE = 15.94% (EBIT 363.7m / Capital Employed (Equity 1.35b + L.T.Debt 934.9m))
RoIC = 9.53% (NOPAT 259.4m / Invested Capital 2.72b)
WACC = 8.50% (E(18.01b)/V(19.04b) * Re(8.92%) + D(1.03b)/V(19.04b) * Rd(1.51%) * (1-Tc(0.29)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.57%
[DCF Debug] Terminal Value 67.99% ; FCFF base≈351.5m ; Y1≈230.7m ; Y5≈105.3m
Fair Price DCF = 23.03 (EV 1.89b - Net Debt 273.9m = Equity 1.62b / Shares 70.3m; r=8.50% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 53.99 | EPS CAGR: -13.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.10 | Revenue CAGR: 24.80% | SUE: 2.47 | # QB: 16
EPS next Quarter (2026-03-31): EPS=1.19 | Chg30d=+0.001 | Revisions Net=+0 | Analysts=19
EPS next Year (2026-12-31): EPS=6.18 | Chg30d=-0.004 | Revisions Net=+1 | Growth EPS=+26.3% | Growth Revenue=+20.6%